Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.

Also called NCT01548378

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 200 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01548378
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01548378. Randomized; quadruple masking; primary purpose treatment. Start 2012-03 (registry gives no type); primary completion 2014-06 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia
Acronym
NL003CLI-II
Condition
Arterial Occlusive Disease
Condition
Ulcers
Condition
Ischemia
Condition
Peripheral Vascular Disease
Intervention (Genetic)
NL003
Intervention (Genetic)
NL003
Intervention (Genetic)
NL003
Intervention (Other)
Normal Saline
Lead sponsor
Beijing Northland Biotech. Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct01548378
Content hash
4617e27a2340ef2a43a0985ae72f90bce8874dcea01bd3c8dee246363acfa041